Geneva v. Marsam
Executive Summary
Geneva filed a countersuit against its joint venture partner following the break-down of settlement negotiations, alleging that generics injectables maker Marsam has contacted "existing Geneva/Marsam customers and request[ed] to sell products under the Marsam label during the period that the partners were attempting to resolve matters in dispute" ("The Pink Sheet" Aug. 31, In Brief). In a July 22 lawsuit, Marsam charged that Geneva has "engaged in a secret course of self-dealing at Marsam's expense" ("The Pink Sheet" July 27, T&G 1).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: